Skip to main content
. 2023 Oct 5;18(10):e0287766. doi: 10.1371/journal.pone.0287766

Table 1. Attributes and levels in module 1.

Effect category Attribute Levels
Treatment type Route of administration

  • Oral

  • Injection

  • Intravenous
Benefits Chance of complete response

  • 50 out of 100 (50%)

  • 20 out of 100 (20%)

  • 0 out of 100 (0%)
Progression-free survival (time until cancer gets worse)

  • 30 months

  • 18 months

  • 12 months
Toxicities Gastrointestinal problems

  • No stomach problems

  • Severe diarrhea

  • Severe nausea
Neurotoxicity No problems with the nervous system

  • Peripheral neuropathy

  • CNS neurotoxicity
Insomnia

  • No insomnia

  • Mild insomnia

  • Severe insomnia
Adverse-event risks Chance of cytokine release syndrome (CRS)

  • 0 out of 100 (0%)

  • 3 out of 100 (3%)

  • 5 out of 100 (5%) or

    10 out of 100 (10%)

CNS = Central nervous system.